NEONC TECHNOLOGIES HOLDINGS, INC. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
NeOnc Technologies (NTHI; $67.9M market cap) announced positive Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma (24 patients, intent-to-treat). Primary endpoint met: 6-month progression-free survival 48.9% (95% CI 26.3–68.1) vs pre-specified 20% standard-of-care benchmark (p=0.0047, one-sided). Median overall survival 26.09 months from recurrence (vs historical 6–9 month salvage benchmark); 86.7% alive at 6 months, 60.9% at 12 months. Five of 24 patients remain on treatment; no major toxicities reported. Company plans Type B FDA meeting to align on registrational (Phase 3) path.
Why this rating
Positive clinical data de-risks development pathway for a $67.9M-cap biotech; meets primary endpoint with strong OS signal 3–4× historical controls. Single-arm uncontrolled trial limits certainty; FDA approval not assured. Material but not transformational until Phase 3 confirms.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.